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European guidelines recommend the use of the Systematic COronary Risk Evaluation
(SCORE) to assess 10-year risk of fatal cardiovascular events in people aged 40 to 65. The
SCORE Older Persons (SCORE OP, 5-year and 10-year versions) was recently developed
for people aged 65 or older. We assessed the performance of these risk scores in predicting
fatal cardiovascular events in older persons in Berlin.
Methods and findings
Data from the Berlin Initiative Study (BIS), a prospective, population-based study of older
persons recruited from a German public health insurance company database were used.
1,657 participants aged 70 or older without reported previous myocardial infarction were
included. We assessed calibration by comparing predicted risks to observed (for 5-year ver-
sions, 5y) or projected (for 10-year versions) probabilities. During follow-up (median: 4.8
years), 118 cardiovascular deaths occurred. The calibration assessment of the SCORE OP-
H 5y and SCORE OP-L 5y equations revealed 2.1- and 1.5-fold overestimation. Comparing
10-year versions, the SCORE OP showed better discrimination ability compared to the
SCORE (C-indices of around 0.80 compared to 0.72) and the SCORE for high-risk regions
showed the best calibration (chi-square = 29.68). The SCORE OP overestimated the true
risk; 519 and 677 events were predicted using the low-risk and high-risk region SCORE OP
equations compared to 397 to 399 events projected based on BIS follow-up data (predicted/
actual ratios of 1.3 and 1.7).
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Conclusions
Given the low transportability of the SCORE OP observed in our population, we caution
against its use in routine clinical practice until further information is available to avoid possi-
ble overtreatment among older persons in Berlin.
Introduction
Cardiovascular (CV) diseases are a leading cause of morbidity and are responsible for approxi-
mately 40% of deaths in the European Union[1] and 30% of deaths worldwide[2]. As most
major CV risk factors are modifiable and can be targeted in preventive strategies[3–6], applica-
tion of risk stratification tools remain of increasing importance and is suggested in the major-
ity of CV disease guidelines[7,8].
More than 363 prediction models for CV disease have been developed over the last decades
[9]. Generally, most known are the risk scores developed in the Framingham Heart Study[10–
12]. The Systematic COronary Risk Evaluation (SCORE) was developed in 2003 to predict the
10-year risk of CV disease mortality in European populations using data from twelve European
cohort studies[13]. The original SCORE is recommended for individuals aged 40 to 65 by the
European guidelines on CV disease prevention from the European Society of Cardiology[14],
and has been re-calibrated in various European countries to account for differences in mortal-
ity rates and risk factor distributions[15–18].
Since the majority of risk scores have been developed using data from primarily middle-
aged populations, it remains unknown how well they perform in older populations[19,20].
With steadily increasing life expectancy, the need for valid CV risk assessment tools for older
individuals is becoming more pressing[21,22]. Indeed, fewer than 20% of all fatal CV events
occur between ages 40 and 65 in Europe[23]. Furthermore, since relationships between indi-
vidual risk factors and CV events are known to change with age[19], it seems unlikely that fatal
CV event risk scores based on coefficients estimated from a mostly middle-aged population
provide reliable estimates of the actual probabilities in older persons[20,22].
Based on this rationale, an updated version of SCORE was developed in 2015 to predict the
risk of fatal CV events specifically for persons aged�65 (SCORE Older Persons, SCORE OP)
[22].
Until recently, the SCORE OP had not been externally validated; the newly published study
calls for further validations of this risk tool[24]. Our objective was to assess calibration and dis-
crimination of SCORE OP in a prospective cohort study of individuals aged�70 in Berlin.
Our secondary aim was to compare the 10-year predictive performance of SCORE OP and
SCORE in this cohort.
Methods
Study population
We used data from the ongoing Berlin Initiative Study, a longitudinal, population-based
cohort study of adults aged�70 with biennial follow-up visits. Details of the study design have
been previously described[25]. In brief, starting in November 2009, participants were selected
using age and sex-stratified random sampling from a database of one of the largest German
health insurance companies in the Berlin region (Allgemeine Ortskrankenkasse (AOK) Nor-
dost) that covers about 50% of older persons in the Berlin region. Oversampling was
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conducted to increase participation among women and the highest age strata[26]. At the end
of the recruitment in June 2011, a total of 2,069 individuals (52.6% female, mean age 80.4
years) completed baseline assessment at one of 13 clinical centers across Berlin. The response
rate of the random sample was 8.1%, and the distribution of common comorbidities, including
myocardial infarction and stroke, was found to be representative of the Allgemeine Ortskran-
kenkasse Nordost source population[26]. An administrative censorship date of September
30th, 2015 was used to ensure endpoint information completeness. In accordance with the eli-
gibility criteria used to select participants in the development of the original SCORE risk
scores, all participants with follow-up information who self-reported no previous history of
myocardial infarction at baseline were included. Written informed consent was obtained from
all participants prior to recruitment. The Berlin Initiative Study was approved by the ethics
committee of Charite´ –Universita¨tsmedizin Berlin, Germany (EA2/009/08).
Risk scores
The following risk scores were selected for external validation:
• SCORE OP-H 5y: European risk score for 5-year fatal CV events among older persons in
high-risk regions[22]
• SCORE OP-L 5y: European risk score for 5-year fatal CV events among older persons in
low-risk regions[22]
• SCORE OP-H: European risk score for 10-year fatal CV events among older persons in
high-risk regions[22]
• SCORE OP-L: European risk score for 10-year fatal CV events among older persons in low-
risk regions[22]
• SCORE-H: European risk score for 10-year fatal CV events among adults in high-risk
regions[13]
• SCORE-L: European risk score for 10-year fatal CV events among adults in low-risk regions
[13]
Since Germany is considered to be between a high- and low-risk region[27], we validated
both versions (for definitions, see [14]).
The published formulas, parameters, and coefficients were used for the computation of the
risk scores. Of the two original parallel SCORE estimation models, we used the simpler version
(with total cholesterol), since no superiority was demonstrated by the model including total
cholesterol to the high-density lipoprotein cholesterol ratio.[13] Additionally, we used the cor-
rected version of the original SCORE formula, which was characterized by a mathematical
inconsistency.[28] In the 2003 publication, the overall risk for fatal CV events (R) was esti-
mated as the sum of two risks; the risk for coronary heart disease death (RCHD) and risk for
non-coronary CV disease death (Rnon-CHD CVD) as follows:
R ¼ RCHD þ Rnon  CHD CVD
Defining the risk of CV mortality in this way is not suitable for participants with high-risk
profiles since the sum of the two specific risks can exceed one. For this reason, we used a sim-
ple correction to estimate the overall risk, assuming cause-specific risk independence:
R ¼ 1   ð1   RCHDÞ � ð1   Rnon  CHD CVDÞ
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This correction was initially proposed by Støvring et al. as the first step in their approach
aiming to account for competing events in the SCORE model.[28]
Since we are validating these scores in an increased risk population due to advanced age, we
have applied this approach to avoid implausible probabilities exceeding 100%.
Risk factors
The following variables used in the models were assessed at baseline during a face-to-face
interview: age as an integer, sex, the mean value of two consecutive blood pressure measure-
ments, HDL and total cholesterol levels (converted from mg/dl to mmol/l dividing by 38.67),
self-reported current smoking status, diabetes mellitus status (as determined by self-reported
use of antidiabetic medication and/or measured HbA1c level >6.5%), and self-reported use of
antihypertensive medication.
Endpoint definition
In the Berlin Initiative Study, information about participant deaths was obtained from several
sources. When no reply to a follow-up invitation letter was received and the participant could
not be reached, the general practitioner on file for the participant was contacted to inquire
about vital status (and date of death, if deceased). Occasionally, participants’ relatives con-
tacted the study team directly about death events. If no information could be obtained from
these sources, AOK Nordost records were used to determine vital status. Berlin Initiative
Study staff additionally obtained records from the Berlin death certificates archive to validate
all deaths, confirm dates, and obtain information on causes of death. Independent of the death
certificate information, the study team attempted to obtain archived medical discharge letters
for all in-hospital deaths as supplemental information to help correctly classify the cause of
death. CV death was defined as death due to fatal myocardial infarction, fatal coronary heart
disease, sudden cardiac death, death due to other cardiac diseases such as heart failure, fatal
cerebrovascular disease (ischemic stroke, subarachnoid hemorrhage, intracerebral hemor-
rhage), and death due to peripheral occlusive arterial disease (complications of an aortic aneu-
rysm, organ ischemia, ischemia). Ambiguous cause of death information were discussed and
final coding decisions were made by two medical doctors without knowledge of individuals’
risk factor profiles. In cases where mortality was confirmed but cause of death could not be
ascertained due to insufficient information, we assumed death by non-CV cause in the pri-
mary analysis.
Statistical analyses
Participants’ baseline risk factors are reported as frequencies and percentages or using means
and standard deviations for categorical and continuous variables. Person-years were calculated
from the date of recruitment to the individual’s death date (as confirmed by a death certifi-
cate), or the date of the last available study visit in cases of loss to follow-up, or the date of
administrative censorship (September 30, 2015).
Associations between the predicted risks from each of the risk estimation systems were
assessed using pairwise Spearman’s rank correlation coefficients. We then computed overall
and CV-specific mortality rates as ratios of the number of observed events to the total amount
of observed person-years with 95% Poisson exact confidence intervals.
For each prognostic model, and for both high- and low-risk region versions, we computed
predicted risks for all individuals. In a second step, we grouped individuals according to deciles
of the predicted risk and assessed calibration for each predicted risk decile group. The “actual”
probability of an event was compared to the mean of the predicted risks in each decile group.
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This comparison was conducted both graphically using a calibration plot and, to allow for
comparability with previous studies, using the Nam-D’Agostino chi-square test[29]. We fur-
ther compared the overall number of “actual” and predicted events across the decile groups to
assess calibration-in-the-large for each risk score.
Given that the Berlin Initiative Study follow-up was shorter than 10 years, we performed
calibration assessment using five years of the observed follow-up data for the SCORE OP risk
equations (SCORE OP-H 5y and SCORE OP-L 5y) as the primary analysis. In this analysis, the
calibration assessment was performed using the Kaplan-Meier estimates as “actual” probabili-
ties. The original SCORE-L and SCORE-H risk equations were unfortunately only reported as
10-year versions. For calibration assessment of the SCORE risk equations, it was therefore nec-
essary to project probabilities of the endpoints beyond the observed follow-up. Specifically,
after creating the predicted risk decile groups, we ran Weibull regression survival models treat-
ing the predicted risk groups as a categorical covariate and the 10-year probabilities for each
decile group projected by the Weibull models were considered “actual” probabilities. In this
secondary analysis, assessment of 10-year calibration was also performed for the SCORE OP
risk equations.
The discrimination ability of each risk score was assessed using the concordance index (C-
index)[30] on the entire observed follow-up.
We computed projected probability estimates and the C-index along with their 95% bias-
corrected and accelerated bootstrapped confidence intervals with 2,000 bootstrap replications.
To check for robustness of our primary results treating unknown causes of death as non-
CV, we re-ran all analyses making the most extreme assumption that all deaths of unknown
cause were of CV nature. Moreover, to confirm that our external validation study findings are
applicable to the general older Berlin population as a whole, we performed an additional sensi-
tivity analysis. All analytical steps described above were repeated in five resampled datasets (by
age and sex strata of the BIS study population), which were generated to create a pseudopopu-
lation exactly representative in terms of size and demographic structure of the 2010 Berlin
population aged 70 or older (data from [31]; see S1 File).
To explore the possible impact on clinical decision making, we applied different “very-
high-risk” thresholds, above which prevention and/or treatment intervention strategies would
be indicated among older persons. Since no such single very-high-risk threshold has been
established, we compared five different hypothetical thresholds (�10%,�15%,�20%,�25%,
and�30%) and calculated the number of very-high-risk persons based on 10-year predicted
risks using the various risk scores. We also computed the percentage of participants classified
as very-high-risk at the various thresholds based on a full Weibull model (with sex, systolic
blood pressure, total cholesterol, HDL cholesterol, smoking status, diabetes and age as covari-
ates and cardiovascular fatal events as the outcome) fitted on BIS data to give a near descrip-
tion of the projected reality at 10 years for our cohort.
All statistical analyses were performed using R v3.4.3 (https://www.R-project.org/) and
RStudio v1.0.153 (https://www.rstudio.com/).
Results
Of the original 2,069 Berlin Initiative Study participants, 412 people who self-reported a his-
tory of myocardial infarction or had missing information on past myocardial infarction, on
one or more risk factors included in the SCORE OP equations, or lacked any follow-up were
excluded (Fig 1). Baseline characteristics of the 1,657 remaining included participants, as well
as mean values for predicted risks estimated by SCORE OP-H 5y, SCORE OP-L 5y, SCORE-H,
SCORE-L, SCORE OP-H, and SCORE OP-L are displayed in Table 1. During the observed
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follow-up period (median: 4.8 years), a total of 324 deaths were recorded, of which 118
(36.4%) were CV deaths. In total, participants contributed 7,370.3 person-years, and the over-
all mortality and CV-specific fatal event rates in the cohort were 44.0 (39.3 to 49.0) and 16.0
(13.3 to 19.2) per 1,000 person-years.
A correlation plot illustrates the distribution of the participants’ predicted probabilities of
the various prognostic models and correlations between the individual scores (S1 Fig in S1
File). As expected, both high-risk and low-risk region pairs from the same models were highly
correlated (Spearman’s rho 0.99–1.00), as well as the 5- and 10-year versions of the SCORE OP
(rho = 0.99–1.00). Overall, we observed moderate correlation between all SCORE and SCORE
OP equations (0.76–0.78).
The calibration of both the SCORE OP-H 5y and the SCORE OP-L 5y equations were
assessed using observed probabilities (Fig 2). In total, 302 fatal CV events were predicted by
the SCORE OP-H 5y while 142 fatal CV events were estimated without accounting for compet-
ing risks, showing an overestimation (predicted/actual ratio = 2.13). This score systematically
overestimated the true risk (chi-square = 139.2, Fig 2A and 2B). The SCORE OP-L 5y also
showed overestimation, but to a lesser extent, with 215 predicted compared to 142 observed
events (ratio = 1.51, chi-square = 39.7, Fig 2C and 2D). Again, a systematic overestimation was
observed across most of the risk score decile groups.
Fig 1. Flow chart showing berlin initiative study participant inclusion/exclusion criteria for this external
validation study.
https://doi.org/10.1371/journal.pone.0231097.g001
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For the secondary analysis, after grouping individuals according to deciles of predicted risk,
we ran Weibull regression survival models. Weibull regression assumptions were fulfilled in
all models (see diagnostic plots; S2 Fig in S1 File). Actual and predicted SCORE-H probabili-
ties are displayed in Fig 3A. The corresponding calibration plot is shown in Fig 3B. Globally,
SCORE-H predicted 372 expected events over ten years, and 382 actual events were projected
(ratio = 0.97, chi-square = 29.7). The discrimination ability of SCORE-H as measured by the
C-index was 0.72 (0.67 to 0.76).
The corresponding probabilities for SCORE-L are illustrated in Fig 3C. In eight decile
groups, predicted probabilities were underestimated (Fig 3D). In total, the number of actual
events projected was 384 while only 258 events were expected based on the SCORE-L (pre-
dicted/actual ratio = 0.67, chi-square = 117.6). The C-index for discrimination was found to be
0.72 (0.67 to 0.77).
Compared to SCORE-H, the 10-year SCORE OP-H equation designed for older persons
had a higher discrimination ability in our study population (C-index = 0.79, 0.75 to 0.83). How-
ever, the SCORE OP-H overestimated risk in each decile group (Fig 4A; chi-square = 327.9).
This systematic overestimation is visible in the calibration plot (Fig 4B). The SCORE OP-H pre-
dicted 677 events, while only 399 actual events were projected, a considerable overestimation
(ratio = 1.70). Similarly, the 10-year version of the SCORE OP-L, despite its good discrimina-
tion ability (C-index = 0.80, 0.75 to 0.83), overestimated the risk for fatal CV events in eight dec-
ile groups (see Fig 4C and 4D). As illustrated by the calibration plot, this overestimation by
SCORE OP-L was to a lesser extent than for SCORE OP-H (chi-square = 76.3). In total, SCORE
OP-L predicted 519 events compared with 397 projected actual events (ratio = 1.31).
We have provided a summary of all the results previously described in Table 2.
To determine the impact of potential misclassification due to 44 fatalities with unknown
cause of death information, we performed all analyses again under a ‘worst-case’ scenario
assuming that all 44 individuals died due to CV reasons. In this sensitivity analysis, the
SCORE-H still underestimated risk (predicted/actual ratio = 0.88), and the SCORE OP-L
Table 1. Baseline characteristics of the study populationa.
Total (n = 1,657) Males (n = 734) Females (n = 923)
Mean age (SD), years 79.7 (6.7) 80.2 (6.7) 79.2 (6.6)
Current smoking, N (%) 86 (5.2%) 47 (6.4%) 39 (4.2%)
Diabetes, N (%) 414 (25.0%) 200 (27.2%) 214 (23.2%)
Hypertensive treatment, N (%) 1254 (75.9%) 551 (75.3%) 703 (76.3%)
Cholesterol (SD), mmol/l 5.6 (1.2) 5.1 (1.1) 5.9 (1.2)
HDL cholesterol (SD), mmol/l 1.5 (0.5) 1.3 (0.4) 1.7 (0.4)
Mean systolic blood pressure, mmHg (SD) 147.0 (22.8) 147.3 (22.8) 146.7 (22.7)
Mean diastolic blood pressure, mmHg (SD) 82.0 (14.5) 82.4 (14.6) 81.6 (14.4)
Risk scoresb
SCORE OP-H 5y risk (SD) 0.18 (0.17) 0.20 (0.16) 0.17 (0.17)
SCORE OP-L 5y risk (SD) 0.13 (0.13) 0.16 (0.14) 0.10 (0.12)
SCORE-H risk (SD) 0.22 (0.15) 0.27 (0.15) 0.19 (0.13)
SCORE-L risk (SD) 0.16 (0.11) 0.17 (0.11) 0.14 (0.11)
SCORE OP-H risk (SD) 0.41 (0.27) 0.45 (0.25) 0.37 (0.27)
SCORE OP-L risk (SD) 0.31 (0.24) 0.36 (0.23) 0.28 (0.24)
aAll participants were enrolled between 2009–2011.
bSCORE OP[22] and SCORE[13] risk scores are described in detail in the Methods section. H and L indicate high- and low- cardiovascular risk regions. Unless
otherwise specified, 10-year risk equations were used. 5y indicates 5-year risk equations.
https://doi.org/10.1371/journal.pone.0231097.t001
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overestimated risk (ratio = 1.22) (S1 Table in S1 File). Consistent results were obtained upon
repeating all analyses in the pseudopopulation dataset with the same size and age-sex structure
of the 2010 Berlin older population, obtained by resampling (see S1 File).
We found that using SCORE OP compared to SCORE led to more individuals classified as
“very-high-risk” at hypothetical thresholds beyond 10% (Table 3). For example, using a 20%
Fig 2. Panel a) shows observed Kaplan-Meier probabilities to be free of fatal cardiovascular (CV) events at a given time point grouped by deciles
of risk as predicted by SCORE OP-H 5y (5-year risk equation for high-risk regions). The right y-axis scale shows the probability of the
complementary event: occurrence of a fatal CV event before a given time point in the counterfactual scenario of no competing events (if we
assume independent competing risks). The legend indicates the average predicted risk of having a fatal CV event within each decile group of risk.
Panel b) shows the calibration plot for SCORE OP-H 5y comparing the predicted mean risk (corresponding to ones in the legend of Panel a)) to
the actual fatal CV event probabilities within five years (corresponding to the intersection between the curves and the right Y-axis in Panel a)) for
each decile group. We report 95% confidence intervals. Panels c) and d) show the results as described in Panels a) and b) for SCORE OP-L 5y
(5-year risk equation for low-risk regions).
https://doi.org/10.1371/journal.pone.0231097.g002
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cut-off, which would be reasonable given the European Society of Cardiology’s recommenda-
tion to select a threshold higher than 10% in older persons[14], results in the following per-
centage of participants being classified as “very-high-risk” per score: SCORE-H: 45.9%
SCORE-L 25.0%, SCORE OP-H 71.2%, and SCORE OP-L 56.5%. According to the full Wei-
bull model fitted on BIS data, 40.9% of BIS participants should be classified as “very-high-
risk”.
Fig 3. Panel a) shows both observed (Kaplan-Meier, dotted lines) and projected (Weibull regression model, solid lines) probabilities to be free of fatal
cardiovascular (CV) events at a given time point grouped by deciles of risk as predicted by SCORE-H (for high-risk regions). The right y-axis scale
shows the probability of the complementary event: occurrence of a fatal CV event before a given time point in the counterfactual scenario of no
competing events (if we assume independent competing risks). The legend indicates the average predicted risk of having a fatal CV event within each
decile group of risk. Panel b) shows the calibration plot for SCORE-H comparing the predicted mean risk (corresponding to ones in the legend of Panel
a)) to the actual fatal CV event probabilities within ten years (corresponding to the intersection between the curves and the right Y-axis in Panel a)) for
each decile group. We report 95% bias-corrected and accelerated bootstrapped confidence intervals. Panels c) and d) show the results as described in
Panels a) and b) for SCORE-L (for low-risk regions).
https://doi.org/10.1371/journal.pone.0231097.g003
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To further explore differences in performance of the two score systems among older per-
sons, we compared fatal CV event risk predicted by the two risk scores for six hypothetical risk
profiles based on risk factors. We created high-, medium-, and low-risk examples for females
and males across the entire age spectrum from 60 to 100 years (see Fig 5). We found that
SCORE OP predicted higher risks compared to SCORE in female individuals aged�75 and in
male individuals aged�78.
Fig 4. Panel a) shows both observed (Kaplan-Meier, dotted lines) and projected (Weibull regression model, solid lines) probabilities to be free of
fatal cardiovascular (CV) events at a given time point grouped by deciles of risk as predicted by SCORE OP-H (for high-risk regions). The right y-
axis scale shows the probability of the complementary event: occurrence of a fatal CV event before a given time point in the counterfactual scenario
of no competing events (if we assume independent competing risks). The legend indicates the average predicted risk of having a fatal CV event
within each decile group of risk. Panel b) shows the calibration plot for SCORE OP-H comparing the predicted mean risk (corresponding to ones
in the legend of Panel a)) to the actual fatal CV event probabilities within ten years (corresponding to the intersection between the curves and the
right Y-axis in Panel a)) for each decile group. We report 95% bias-corrected and accelerated bootstrapped confidence intervals. Panels c) and d)
show the results as described in Panels a) and b) for SCORE OP-L (for low-risk regions).
https://doi.org/10.1371/journal.pone.0231097.g004
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Discussion
In this prospective, population-based study of Berlin older individuals, the SCORE OP 5y sub-
stantially overestimated the true risk of fatal CV events. In the 10-year comparison, interest-
ingly, the SCORE equation recommended for persons aged from 40 to 65, showed better
Table 2. Risk scores: Measures of validity.
Risk scorea Predicted number of fatal
cardiovascular events











high-risk (0.75 to 0.83)
Regions
SCORE 302 142 2.13 139.16
OP-H 5y (p<0.001)





low-risk (0.75 to 0.83)
Regions
SCORE 215 142 1.51 39.68
OP-L 5y (p<0.001)
SCORE 519 397 1.31 76.29
OP-L (p<0.001)
SCORE-H 372 382 0.97 29.68 0.72
(p = 0.001) (0.67 to 0.76)
SCORE-L 258 384 0.67 117.63 0.72
(p<0.001) (0.67 to 0.77)
aSCORE OP[22] and SCORE[13] systems have been previously described elsewhere. H and L indicate high- and low- cardiovascular risk regions. 5y indicates 5-year risk
equations. All other scores listed are 10-year versions.
bWeibull regression model projections beyond the observed follow-up are reported for 10-year risk scores, leading to small differences in the number of actual events.
5-year risk scores use observed Berlin Initiative Study data only using the Kaplan-Meier estimator.
cRisk score discrimination capability was assessed using the entire observed follow-up data.
https://doi.org/10.1371/journal.pone.0231097.t002
Table 3. Percentage of berlin initiative study participants classified as very-high-riska based on various hypothetical thresholds of cardiovascular mortality pre-
dicted risk.
Prognostic modelb Predicted 10-year risk threshold
�10% �15% �20% �25% �30%
SCORE-H 80.0% 62.8% 45.9% 33.2% 23.5%
SCORE-L 60.9% 39.4% 25.0% 16.3% 10.4%
SCORE OP-H 91.4% 80.4% 71.2% 62.8% 55.8%
SCORE OP-L 79.9% 67.2% 56.5% 47.6% 40.7%
Full Weibull model fitted on BIS data 58.1% 48.2% 40.9% 33.7% 28.7%
aIn this hypothetical example, only individuals with a predicted risk higher than the threshold are considered very-high-risk persons. This simplification is only intended
to illustrate possible clinical implications of the use of prognostic tools.
bSCORE[13] and SCORE OP[22] risk scores have been previously described elsewhere. H and L indicate high- and low- cardiovascular risk regions. The full Weibull
model fitted on BIS data includes sex, systolic blood pressure, total cholesterol, HDL cholesterol, smoking status, diabetes and age as covariates and cardiovascular fatal
events as the outcome to give a near description of the projected reality at 10 years for our cohort.
https://doi.org/10.1371/journal.pone.0231097.t003
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calibration than the SCORE OP, developed specifically for persons aged from 65 to 80[22].
The SCORE OP did, however, demonstrate slightly superior discrimination capabilities as
assessed by the C-index, likely attributable to the higher number of included risk factors.
Because the prevalence of CV risk factors and their estimated effects on CV outcomes are
known to change with increasing age[20,32], the SCORE OP was developed to correct for a
suspected overestimation of fatal CV event risk as predicted by the original SCORE in persons
aged�65[22]. The SCORE development dataset was comprised largely of middle-aged indi-
viduals (only three cohorts out of 12 included participants aged�70, and no cohort included
individuals aged>80). Because of this, it was hypothesized that the estimated prediction
model beta coefficients were inappropriately large in magnitude, likely overemphasizing the
contribution of these risk factors to the predicted risk in older persons[20,22,32,33]. Since the
Fig 5. We compared SCORE-L, SCORE-H, SCORE OP-H and SCORE OP-L predicted 10-year risks for six risk profiles; high-,
medium- and low-risk for females and males. The high-risk profile was constructed using data from a hypothetical diabetic, current
smoker with a systolic blood pressure of 180 mmHg, total cholesterol level of 8 mmol/l, and HDL cholesterol level of 1 mmol/l. The
medium-risk profile was created using mean values for all variables based on the baseline characteristics of Berlin Initiative Study
participants (see Table 1). The low-risk profile was constructed using data from a hypothetical non-diabetic, current non-smoker with a
systolic blood pressure of 120 mmHg, total cholesterol level of 4 mmol/l, and HDL cholesterol level of 2 mmol/l. The high- and low-risk
reference values for systolic blood pressure and total cholesterol were taken from the minimum and maximum values reported in the
SCORE chart.
https://doi.org/10.1371/journal.pone.0231097.g005
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levels of traditional CV risk factors are known to be elevated in older persons, the use of inap-
propriately large coefficients for this population was expected to result in substantial overesti-
mation of the true fatal CV event risk using the SCORE[22].
The SCORE OP is based on re-estimated beta coefficients using data from people aged�65
also including additional parameters (diabetes and HDL) in an attempt to correct the expected
overestimation. Based on this rationale, the use of SCORE OP is currently suggested as an
alternative by the European Society of Cardiology and European Society of Hypertension
guidelines for the management of arterial hypertension in older individuals (aged�65)[34].
The idea that the SCORE gives higher estimates of risk compared to the SCORE OP among
older persons was reinforced by findings from a cross-sectional study in Spain[35,36] and the
charts comparison presented in the SCORE OP development paper (p.8)[22]. However, these
two comparisons were based solely on the 65–69 age group. No attempt was made to compare
predictions across all ages 65 and above.
In our cohort comprised of older persons, we found that SCORE OP yielded higher risk
estimates than SCORE (with mathematical correction). The same result was found in the only
published external validation of the SCORE OP[24]. While the authors attributed this incon-
sistency with the previous cross-sectional study[35,36] to a difference in the methods used, we
think it may have arisen because of a difference in age composition of the participants. Upon
comparing the scores designed for low-risk regions, we confirm that in the age group 65–68,
the SCORE-L yields higher risk estimates than the SCORE OP-L for medium- and high-risk
individuals (see Fig 5). However, this is not true for any of the risk profiles in individuals aged
�70; in these individuals, the risk estimated by SCORE OP-L consistently exceeds that of
SCORE-L. We observed a similar behavior upon comparing the high-risk region risk scores
(Fig 5).
Moreover, we found a lower transportability of the SCORE OP compared to the original
SCORE. This is likely explained by a difference in the distribution of unmeasured risk factors
and baseline CV fatal risk in our cohort compared to the SCORE OP development dataset.
The SCORE OP development dataset was composed of 85% individuals from Norway and
included no German cohorts, while the SCORE development dataset included a German
cohort and a balanced distribution of individuals from several European countries. Differences
in the definition of CV risk factors included in the models or in the true underlying hazard
ratios may have led to the unsuitability of the SCORE OP coefficients. For example, in the
SCORE OP development dataset, included cohort prevalences of diabetes mellitus ranged
from 6% to 7% in females and 4% to 7% in males[22]. These prevalences are considerably
lower than the diabetes mellitus prevalences observed in the Berlin Initiative Study (23% in
females and 27% in males, which align with German prevalence figures among older persons
[37]) and it is likely a difference in the definition of diabetes contributed to the observed low
transportability of the SCORE OP.
We found the best performing risk score among older persons in Berlin was the SCORE-H
developed for high-risk regions despite that Germany’s fatal CV risk is considered to be
between that of high- and low-risk regions, with a tendency towards the latter[27]. The fact
that the SCORE-L seems more appropriate in middle-aged persons while the SCORE-H seems
better suited among older persons suggests that in the Berlin population, the observed differ-
ence in risk prediction is likely explained by differences in baseline survivorship functions
(determined by age, sex, unmeasured risk factors) of these age groups rather than by differ-
ences in the coefficients of classical risk factors such as cholesterol, blood pressure and smok-
ing. In fact, SCORE developers used the same coefficients in both regional versions.
In general, the performance of the SCORE equations was surprisingly good, especially con-
sidering that this risk score was developed in 2003 using data from cohort studies with
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recruitment periods between 1967 and 1991 and that the incidence and treatment strategies
for CV diseases changed substantially over the last decades[38].
Recently, the SCORE OP was subjected to external validation for the first time in a cohort
of 6,590 older individuals aged between 65 and 79 living in Norfolk, UK[24]. Their results
about the transportability of the SCORE OP and SCORE among older persons were divergent
compared to ours. In this UK population, the SCORE OP showed “excellent calibration”, per-
forming better than the SCORE, despite showing low discrimination ability[24]. Interestingly,
in this UK cohort, diabetes prevalence was extremely low, around 3%[24], likely because this
information was only self-reported. This observation provides additional support for our
aforementioned argument that the definition of diabetes plays a crucial role in the transport-
ability of the SCORE OP. Regional differences and the age of the cohort, overall younger than
our study participants, may also have contributed to the discrepancies.
Finally, the SCORE and SCORE-OP were developed without accounting for possible com-
peting events, thus, our calibration used a consistent approach; neither the Weibull model pro-
jections nor the Kaplan-Meier estimates accounted for competing events. We acknowledge,
however, that competing risks do pose a large problem for practical use among older persons,
in whom competing fatal events are common. For this reason, methods have been suggested
for the development of local, updated, recalibrated scores that can be used to inform regional
risk prediction accounting for mortality due to other causes[28].
Study strengths and limitations
Strengths include the prospective design, population-based setting, and availability of compre-
hensive health-related information, providing unique insights into the health of the very old, a
population often excluded from larger studies. Death information is considered to be complete
and was obtained from the Berlin death certificates archive and supplemented with informa-
tion from medical records. Specific cause of death information was consistently extracted
when available. Furthermore, a total of 118 fatal CV endpoints were recorded during observed
follow-up, exceeding the minimum amount needed to properly validate a 10-year prognostic
model over the entire time span (at least 100)[39].
Some limitations should be considered when interpreting our findings. First, we compared
predicted probabilities to projected ones since the Berlin Initiative Study follow-up data were
available for less than 10 years. However, the Weibull diagnostic plots indicate fulfillment of
the assumptions of all projection models, and our analyses predicting 5-year risk using
observed data were consistent with the findings using 10-year projected probabilities and thus
confirm our results. A minor drawback to our approach is that the number of “actual” events
is not constant across calibration assessments because it depends on decile groupings of partic-
ipants, which differed for each risk score. However, these “actual” event numbers did not differ
substantially (range: 382 to 399).
Second, the reliability of cause of death information on death certificates is known to be
error-prone, especially among older persons. However, we believe this potential misclassifica-
tion is similar for most population-based settings and was also present in the risk score devel-
opment studies[22].The impact of unknown or unavailable cause of death information as
demonstrated by our “worst-case” sensitivity analysis was negligible.
Furthermore, all of the original SCORE endpoints are well-represented in our definition,
with the exception of non-aortic aneurysms, which are very rare events.
Finally, the exclusion of subjects with previous history of myocardial infarction was based
on self-reported information. However, the self-reported nature of this information in our
study is unlikely to be problematic, since this exclusion criterion was introduced during the
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SCORE development only to ensure overall CV health in the considered sample and not for
the purpose of excluding participants not at risk for the outcome.
Nonetheless, we suggest against excluding people with a predefined CV event from future
prognostic models developed to predict CV mortality risk, as this limits prediction score
usability. This is a particularly important consideration among older persons, in whom preva-
lent non-fatal CV events are common.
Implications and suggestions for future research
This external validation study shows that the SCORE OP overestimates CV mortality risk
among Berlin older persons, which ultimately leads to the classification of more individuals to
higher levels of CV mortality risk at most hypothetical very-high-risk thresholds, above which
intervention strategies would be indicated. We believe our results may have important impli-
cations since overestimation of risk in these individuals may lead to overtreatment in a poten-
tially vulnerable population already prone to polypharmacy[40], which is known to lead to
adverse drug events or interactions and increase health care costs[41]. Our results underscore
the importance of external validation of prediction tools before clinical use. Mass medicaliza-
tion may result from an overestimation due to lack of transportability of these tools or from
setting too low of a risk threshold[42]. This potential danger is illustrated by the higher num-
ber of BIS participants who would be classified as very-high-risk for 10-year fatal CV risk
according to the SCORE OP compared to the reality.
In our external validation study, the original SCORE developed for high-risk regions per-
formed best in older persons living in Berlin. Our findings are very different from the ones
obtained in the first SCORE OP external validation study conducted among older adults in the
UK; however, both studies do not support the use of SCORE OP in clinical practice. Therefore,
the challenge of finding a valid tool for profiling risk among older European individuals may
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